CFRXQ (ContraFect) ROCE %: 0.00% (As of Sep. 2023)

What is ContraFect ROCE %?

ContraFect CFRXQ -90.00% ROCE % is 0.00% as of Sep. 2023.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ContraFect's annualized ROCE % for the quarter that ended in Sep. 2023 was 0.00%.

ContraFect (OTCPK:CFRXQ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ContraFect ROCE % Related Terms

ContraFect ROCE % Historical Data

* Premium members only.

The historical data trend for ContraFect's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ContraFect ROCE % Chart

ContraFect Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-85.45

-107.12

-97.82

-94.87

-209.05

ContraFect Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROCE %	Get a 7-Day Free Trial															-583.27	0.00	-9,589.17	-1,734.17	0.00

ContraFect ROCE % Calculation

ContraFect's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-56.889	/	( ( (66.762 - 12.174)	+	(20.679 - 20.84) )	/ 2 )
	=	-56.889	/	( (54.588	+	-0.161)	/ 2 )
	=	-56.889	/	27.2135
	=	-209.05 %

ContraFect's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	-26.708	/	( ( (19.252 - 16.473)	+	(9.125 - 12.323) )	/ 2 )
	=	-26.708	/	( ( 2.779	+	-3.198 )	/ 2 )
	=	-26.708	/	-0.2095
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 0.00% mean?

ContraFect (CFRXQ) has a ROCE % of 0.00% as of Sep. 2023.

Is ContraFect's ROCE % too high?

ContraFect's current ROCE % is 0.00%.

How does ContraFect's ROCE % compare to ADTX and RUBY?

ContraFect's ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. ContraFect's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is ContraFect stock overvalued right now?

ContraFect (CFRXQ) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For ContraFect (CFRXQ), the current ROCE % is 0.00% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ContraFect Business Description

Industry Healthcare Biotechnology

Comparable Companies ADTX RUBY NBY NBRVF BXRX INM GLMD HSTO BLCM SPRC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Address 28 Wells Avenue, 3rd Floor, Yonkers, NY, USA, 10701

Website https://www.contrafect.com

ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.